Endpoint Ventures

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Shasqi, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2018. It specializes in the development of a unique platform known as CAPAC (Click Activated Protodrugs Against Cancer), which utilizes click chemistry for localized drug activation. This innovative approach allows for the activation of chemotherapeutic agents directly at tumor sites, thereby concentrating the drug's effects where they are most needed while minimizing systemic toxicity. The technology involves injecting a polymer gel that contains a click chemistry reagent in the tumor area, which subsequently activates a systemically administered protodrug when they interact. Shasqi's platform has demonstrated efficacy in human trials, indicating its potential to enhance cancer treatment outcomes and paving the way for future advancements in click-chemistry-based therapies.

Viosera Therapeutics, Inc. is focused on developing therapies to combat antibiotic resistance, particularly targeting methicillin-resistant Staphylococcus aureus (MRSA). Founded in July 2016, the company has its headquarters in Sunnyvale, California, and an additional office in St. Louis, Missouri. Viosera is known for its innovative approach that utilizes artificial intelligence to predict and block the evolution of drug resistance in both cancer and bacterial infections. Its primary product, VT1, is specifically designed to treat MRSA bloodstream infections, allowing healthcare providers to effectively manage and suppress antibiotic resistance, ultimately aiming to enhance patient outcomes.

FidoCure is dedicated to advancing canine cancer care through the use of AI-driven precision medicine. The company has established the largest proprietary learning database for canine cancer by utilizing data from naturally occurring cases and next-generation sequencing. FidoCure focuses on providing personalized medicine services, which go beyond traditional chemotherapy and radiation. By collecting tissue samples for DNA sequencing, the company generates detailed reports that identify genetic mutations influencing treatment options. This approach enables veterinarians and pet owners to implement targeted therapies that specifically address cancer cells, ultimately improving the quality of life for dogs facing cancer. Furthermore, FidoCure bridges the gap between human and veterinary oncology, fostering comparative oncology and creating innovative drug development opportunities that benefit both pets and humans.

Synkrino Biotherapeutics is a biotechnology platform focused on discovering and developing novel drug targets derived from the immune systems of patients. The company aims to address diseases driven by immune responses and inflammation, utilizing its AI Immunology Discovery Engine (AIDE Engine). This innovative technology employs neural networks and machine learning to analyze immune tissue, allowing for the systematic identification of biologically-valid drug targets. In addition to its therapeutic development, Synkrino is also creating a rapid, portable field test for the RNA virus responsible for COVID-19, adapting its analytic protocols to enhance community public health screening. Through these initiatives, Synkrino Biotherapeutics seeks to improve patient outcomes and healthcare delivery.

Meru Health, Inc. is a digital healthcare company that focuses on improving the lives of individuals dealing with mental health issues such as depression, anxiety, and stress. Founded in 2015 and based in San Mateo, California, with additional offices in Palo Alto and Helsinki, Meru Health develops a mobile application that connects users to licensed therapists through a structured 12-week program. This program combines continuous remote clinician support with at-home lessons, cognitive behavioral therapy, and coaching on sleep and nutrition. By offering clinically proven and cost-effective digital therapeutic solutions, Meru Health aims to empower patients and enhance the efficiency of mental health treatment.

HelpWear Inc., founded in 2015 and based in Toronto, Canada, specializes in developing innovative home heart monitoring solutions aimed at enhancing at-home healthcare. The company focuses on creating affordable and accessible products tailored to the needs of patients and the requirements of the healthcare system. Its flagship device is a waterproof wearable that monitors cardiovascular health, detects heart attacks, and transmits real-time alerts to medical facilities through an embedded emergency contact system. This technology enables patients with heart conditions to receive timely support from healthcare professionals while keeping them informed about their health status and necessary checkups.

BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.